Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,536.00
+41.50 (1.66%)
Jul 17, 2025, 3:30 PM JST
Kyowa Kirin Revenue
Kyowa Kirin had revenue of 104.73B JPY in the quarter ending March 31, 2025, a decrease of -0.80%. This brings the company's revenue in the last twelve months to 494.71B, up 8.90% year-over-year. In the year 2024, Kyowa Kirin had annual revenue of 495.56B with 12.06% growth.
Revenue (ttm)
494.71B
Revenue Growth
+8.90%
P/S Ratio
2.68
Revenue / Employee
87.27M
Employees
5,669
Market Cap
1,324.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 866.03B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Shionogi & | 438.27B |
Kyowa Kirin News
- 3 months ago - 35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN - PRNewsWire
- 4 months ago - Amgen Inc (AMGN) and Kyowa Kirin Announce Promising Phase 3 Results for Rocatinlimab in Atopic ... - GuruFocus
- 5 months ago - Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025 - PRNewsWire
- 5 months ago - Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies - Benzinga
- 6 months ago - Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe - Business Wire
- 6 months ago - AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform - GlobeNewsWire
- 7 months ago - Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies - Business Wire
- 8 months ago - Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - Seeking Alpha